Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tefluthrin SCHEMBL20823 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL16536934 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL2740810 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL14427331 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL4622566 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL1920781 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL8769136 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL1898396 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL21112033 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM | |
| Tefluthrin SCHEMBL1963314 | 1.00 | TDP1 (1.00) | TDP1MEN1KMT2ALMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0538246-B1 | PYRETHROID FORMULATIONS OF REDUCED PARESTHESIA | ZENECA INC (US) | 1995-02-22 | — | — | EP | claimed |
| EP-0538246-A1 | PYRETHROID FORMULATIONS OF REDUCED PARESTHESIA. | ICI AMERICA INC (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1990008467-A1 | PYRETHROID FORMULATIONS OF REDUCED PARESTHESIA | ICI AMERICAS INC. (US) | 1990-08-09 | — | — | WO | claimed |
| EP-1339666-B1 | PREPARATION OF 4-METHYL-2,3,5,6-TETRAFLUOROBENZYL ALCOHOL | SYNGENTA LTD (GB) | 2008-04-02 | — | — | EP | disclosed |
| US-6894195-B2 | Preparation of 4-methyl-2,3,5,6-tetrafluorobenzyl alcohol | SYNGENTA LIMITED (GB) | 2005-05-17 | — | — | US | disclosed |
| US-20050054886-A1 | Preparation of 4-methyl-2, 3, 5, 6-tetrafluorobenzyl alcohol | SYNGENTA LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| EP-1332125-B1 | PREPARATION OF 4-METHYL-2,3,5,6-TETRAFLUOROBENZYL ALCOHOL | SYNGENTA LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| US-20040063993-A1 | Preparation of 4-methyl-2,3,5,6-tetrafluorobenzyl alcohol | SYNGENTA LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1339666-A1 | PREPARATION OF 4-METHYL-2,3,5,6-TETRAFLUOROBENZYL ALCOHOL | Syngenta Limited (GB) | 2003-09-03 | — | — | EP | disclosed |
| EP-1332125-A1 | PREPARATION OF 4-METHYL-2,3,5,6-TETRAFLUOROBENZYL ALCOHOL | Syngenta Limited (GB) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002034706-A1 | PREPARATION OF 4-METHYL-2, 3, 5, 6-TETRAFLUOROBENZYL ALCOHOL | SYNGENTA LIMITED (GB) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002034707-A1 | PREPARATION OF 4-METHYL-2,3,5,6-TETRAFLUOROBENZYL ALCOHOL | SYNGENTA LIMITED (GB) | 2002-05-02 | — | — | WO | disclosed |
| EP-0538246-A1 | PYRETHROID FORMULATIONS OF REDUCED PARESTHESIA. | ICI AMERICA INC (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1990008467-A1 | PYRETHROID FORMULATIONS OF REDUCED PARESTHESIA | ICI AMERICAS INC. (US) | 1990-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063993-A1 | Preparation of 4-methyl-2,3,5,6-tetrafluorobenzyl alcohol | METTL14, CYP4F2, METTL3 | TDP1 4018/4885MEN1 1618/4885KMT2A 80/4885 |
| US-20050054886-A1 | Preparation of 4-methyl-2, 3, 5, 6-tetrafluorobenzyl alcohol | ADH1C, ADH1A, TET3 | TDP1 2022/4885MEN1 694/4885KMT2A 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.